Medicine and Dentistry
Pediatrics
100%
Oncology
96%
Acute Lymphoblastic Leukemia
95%
Neoplasm
68%
Sickle-Cell Disease
55%
Malignant Neoplasm
53%
Childhood Cancer
48%
Disease
40%
Idiopathic Thrombocytopenic Purpura
35%
Adolescent
30%
Event Free Survival
29%
Bleeding
28%
Rhabdomyosarcoma
27%
Clinical Trial
25%
Germinoma
25%
Pediatrics Patient
23%
Overall Survival
22%
Methotrexate
21%
Infection
20%
Platelet
19%
Minimal Residual Disease
17%
Ganglioglioma
16%
Osteosarcoma
15%
Apoplexy
15%
Leukemia
14%
Quality of Life
14%
Radiation Therapy
13%
Hematopoietic Stem Cell Transplantation
13%
Neurofibromatosis Type I
12%
Bleeding Disorder
12%
Precursor
11%
Acute Myeloid Leukemia
11%
Bone Marrow Transplantation
11%
Diagnosis
11%
Pediatric Cancer
11%
Thrombosis
10%
Wilms' Tumor
10%
Menorrhagia
10%
Neutropenia
10%
Acute B-Cell Lymphoblastic Leukemia
10%
Group Trial
9%
Arm
9%
Central Nervous System
9%
Magnetic Resonance Imaging
9%
Surgery
9%
Recurrent Disease
9%
Cancer
9%
Transplantation
9%
Ewing Sarcoma
9%
Sarcoma
8%
Medulloblastoma
8%
Lymphoid Leukemia
8%
Pediatric Hematology
8%
Systematic Review
8%
Venous Thromboembolism
8%
Cytarabine
8%
Survival Rate
8%
Diamond-Blackfan Anemia
8%
Risk Stratification
8%
Febrile Neutropenia
8%
Infusion
7%
Soft Tissue Sarcoma
7%
Etoposide
7%
Odds Ratio
7%
Blood Transfusion
7%
Hematopoietic Stem Cell
7%
Sickle Cell
7%
Hypochromic Anemia
7%
Haemophilia
7%
Acute Leukemia
7%
Prognostic Factor
7%
Splenectomy
7%
Toddlers
7%
Progression Free Survival
7%
Adverse Event
6%
Hazard Ratio
6%
Extracorporeal Membrane Oxygenation
6%
Anemia
6%
Vincristine
6%
Prednisone
6%
Symptom
6%
Mercaptopurine
6%
Von Willebrand Factor
6%
Von Willebrand Disease
6%
Drug Megadose
6%
Ganglioneuroblastoma
6%
Central Venous Catheter
6%
Antibiotics
6%
Cyclophosphamide
6%
Cell Transplantation
6%
Brain Tumor
6%
Outpatient
5%
Plexiform Neurofibroma
5%
Asparaginase
5%
Patient with Sickle Cell Disease
5%
Childhood Leukemia
5%
Drug Therapy
5%
Immunoglobulin
5%
Hemoglobin SC Disease
5%
Deep Vein Thrombosis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
57%
Malignant Neoplasm
38%
Sickle Cell Anemia
31%
Chemotherapy
24%
Childhood Cancer
24%
Neoplasm
22%
Methotrexate
21%
Idiopathic Thrombocytopenic Purpura
21%
Disease
20%
Remission
16%
Bleeding
15%
Clinical Trial
14%
Hydroxycarbamide
12%
Event Free Survival
12%
Asparaginase
11%
Neutropenia
11%
Infection
10%
Leukemia
10%
Cytarabine
10%
Germ Cell Tumor
9%
Adverse Event
8%
Rhabdomyosarcoma
8%
Overall Survival
8%
Acute Myeloid Leukemia
8%
Vincristine
7%
Minimal Residual Disease
7%
Solid Malignant Neoplasm
7%
Mouse
7%
Dexamethasone
7%
Etoposide
6%
Cyclophosphamide
6%
Group Trial
6%
Placebo
6%
Prednisone
6%
Pharmacokinetics
6%
Osteosarcoma
6%
Febrile Neutropenia
5%
Mercaptopurine
5%
Asparaginase Macrogol
5%
Iron Deficiency Anemia
5%
Haemophilia
5%
Ewing Sarcoma
5%
Doxorubicin
5%
Protein P53
5%
Bacteremia
5%
Keyphrases
Children's Oncology Group
33%
Acute Lymphoblastic Leukemia
29%
Pediatric
19%
Group Studies
18%
Sickle Cell Disease
16%
Childrens
13%
Tumor
13%
Oncology
12%
Pediatric Patients
12%
Event-free Survival
12%
Germ Cell Tumor
12%
Children with Cancer
11%
Pediatric Oncology
11%
Rhabdomyosarcoma
11%
Chemotherapy
11%
Sickle Cell Anemia
10%
High Risk
10%
Neurofibromatosis Type 1 (NF-1)
10%
Overall Survival
10%
Clinical Trials
9%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
9%
Neurofibromatosis Type I
9%
Newly Diagnosed
9%
Older Adults
9%
Childhood Acute Lymphoblastic Leukemia
8%
Minimal Residual Disease
7%
Methotrexate
7%
Thrombotic Thrombocytopenic Purpura
7%
Leukemia
7%
Immune Thrombocytopenia
7%
Phase II Trial
6%
Zebrafish
6%
Group Reports
6%
Platelet Count
6%
Confidence Interval
6%
Survivors
6%
Splenectomy
6%
Hemophilia
6%
Pegaspargase
5%
Acute Myeloid Leukemia
5%
Bleeding
5%
Hazard Ratio
5%
Childhood Cancer Survivors
5%
Central Nervous System
5%
Osteosarcoma
5%
Phase II Study
5%